Epigral Reports Over Two-Fold Increase in Q4 Profit, Shares Surge
Epigral soars after Q4 PAT jumps over two-fold to Rs 82 cr
Business Standard
Image: Business Standard
Epigral's standalone net profit surged 109.27% to ₹81.93 crore for Q4 FY26, driving shares up 7.79% to ₹1,297. Revenue from operations also saw a 23.29% increase to ₹736.16 crore, attributed to strong volume growth and improved realizations. Despite a year-on-year decline in profit, the company expects continued momentum into FY27.
- 01Standalone net profit increased by 109.27% to ₹81.93 crore in Q4 FY26.
- 02Revenue from operations rose 23.29% QoQ to ₹736.16 crore.
- 03EBITDA climbed 64% QoQ, with an EBITDA margin improvement to 23%.
- 04Sales volume grew 15% QoQ, with plant utilization exceeding 80%.
- 05The company recommended a dividend of ₹5 per equity share for FY26.
Advertisement
In-Article Ad
Epigral, formerly known as Meghmani Finechem, reported a remarkable 109.27% increase in standalone net profit, reaching ₹81.93 crore for the fourth quarter of FY26, compared to ₹39.15 crore in the previous quarter. Revenue from operations also surged 23.29% quarter-on-quarter (QoQ) to ₹736.16 crore, driven by a 15% increase in sales volume and improved realizations. Year-on-year (YoY), however, net profit declined 15.2%, while revenue rose 17.29%. The profit before tax (PBT) stood at ₹110.52 crore, reflecting a 102.42% QoQ increase but a 15.67% YoY decline. The EBITDA for the quarter climbed 64% QoQ to ₹169 crore, with an improved EBITDA margin of 23% compared to 17% in Q3 FY26. The company's diversified product portfolio and ongoing capital expenditure projects are expected to enhance performance amid geopolitical uncertainties. Additionally, the board has recommended a dividend of ₹5 per equity share for the financial year 2025-26.
Advertisement
In-Article Ad
The significant profit increase and revenue growth may lead to enhanced investor confidence and potentially higher stock prices, benefiting shareholders.
Advertisement
In-Article Ad
Reader Poll
Do you think Epigral's growth will continue in FY27?
Connecting to poll...
More about Epigral
Read the original article
Visit the source for the complete story.